Obesity Management

Contraindications and Side Effects

• Contraindications for certain obesity medications include pregnancy, personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, with common side effects being nausea, constipation, diarrhea, vomiting, and headache, as noted by the American Gastroenterological Association 1
• Phentermine/topiramate ER has contraindications such as pregnancy, glaucoma, hyperthyroidism, and use within 14 days of MAOIs, and requires gradual dose escalation, as recommended by the American Gastroenterological Association 1
• Naltrexone/bupropion SR has contraindications including pregnancy, uncontrolled hypertension, seizure disorders, bulimia/anorexia, and use of opioid agonists or MAOIs, as stated by the American Gastroenterological Association 1
• Orlistat has contraindications such as pregnancy, chronic malabsorption syndrome, and cholestasis, and may be useful for patients with obesity and constipation, as noted by the American Gastroenterological Association 1

Medication Considerations

• Phentermine and phentermine-containing medications should be discontinued at least 4 days before procedures requiring anesthesia due to potential refractory hypotension, as recommended by the American Gastroenterological Association 2
• The American Gastroenterological Association clarifies that it was fenfluramine, not phentermine, that was implicated in valvular heart disease, addressing common misconceptions about phentermine 2
• Pharmacological treatment for weight loss is recommended for individuals with a BMI ≥30 kg/m² or a BMI ≥27 kg/m² with weight-related comorbidities, such as hypertension, dyslipidemia, coronary heart disease, type 2 diabetes, or sleep apnea, and only after inadequate response to lifestyle interventions, as supported by the American Academy of Family Physicians and American College of Cardiology 3, 4, 5
• Patients should have attempted and failed to achieve adequate weight loss through lifestyle modifications alone before starting pharmacotherapy, including dietary changes, increased physical activity, and behavioral therapy, as recommended by the American Gastroenterological Association, American Heart Association, American Diabetes Association, and American College of Cardiology 3, 1, 6, 7
• A multimodal approach to obesity treatment is recommended, including reduced caloric intake (500-1000 kcal/day deficit), increased physical activity (initially 30-40 minutes, 3-5 days/week), and behavioral therapy, with a long-term goal of 60-90 minutes of moderate activity daily, as supported by the American Diabetes Association and American College of Cardiology 1, 6, 7

FDA-Approved Medications

• The following medications are approved for weight loss:
• GLP-1 receptor agonists (semaglutide 2.4mg, liraglutide 3.0mg) are recommended as first-line pharmacotherapy with superior efficacy for weight loss, as per the American Diabetes Association and American College of Cardiology guidelines 7

Treatment Efficacy and Safety

• Efficacy and safety should be assessed at least monthly for the first 3 months, then every 3 months, as recommended by the American College of Cardiology 1
• Medications should be discontinued if <5% weight loss is achieved after 12 weeks at maximum tolerated dose, or if serious adverse effects occur, as recommended by the American Diabetes Association and the American Society for Gastrointestinal Endoscopy 1, 5, 8
• Evaluate treatment efficacy at 3 months: if weight loss <5%, consider changing medication or adding another intervention; if weight loss ≥5%, continue treatment with periodic evaluations, as recommended by the American Gastroenterological Association 1

Bariatric Surgery

• Referral for bariatric surgery evaluation may be considered if pharmacotherapy fails after 6-12 months of consistent use, as recommended by the World Health Organization and the National Institute of Diabetes and Digestive and Kidney Diseases 9
• Bariatric surgery can produce substantial weight loss (20-40 kg) in patients with class III obesity, with the Swedish Obese Subjects study demonstrating sustained weight loss of 20 kg at 8 years follow-up for surgically treated patients compared to medically treated patients, as recommended by the American Academy of Family Physicians and American College of Physicians 4, 10

Access to Care and Insurance Coverage

• Medicare and Medicaid explicitly exclude coverage of FDA-approved anti-obesity medications for obesity alone due to cost concerns, limited long-term efficacy data, and historical classification of these medications as "lifestyle drugs" rather than treatments for a chronic disease, as noted by the Medicare Modernization Act of 2003 11
• Anti-obesity medications are often costly, creating significant budget impact concerns for public insurance programs, with global shortages of some medications, especially GLP-1 receptor agonists, further complicating access and increasing costs, as reported by the American Diabetes Association and American College of Cardiology 11
• This coverage gap creates significant disparities in obesity treatment access, with patients with lower socioeconomic status who rely on Medicaid being disproportionately affected by obesity yet having the least access to pharmacological treatments, as highlighted by the American Academy of Family Physicians and American College of Physicians 2
• Research shows these disparities significantly affect health outcomes, including increasing the risk for obesity, diabetes, and diabetes-related complications, as reported by the American Diabetes Association and American College of Cardiology 8